Revert ONLUS   Report issue

Foundation Phase 1

Organization Overview

First Clinical Trial
2017
NCT03282760
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Associazione Oncologica Milanese AmoLaVita ONLUS | Associazione Revert ONLUS

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Chronic Progressive (Phase 1)

Neoplasm Metastasis (Phase 1)

Sclerosis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 6